Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Goodwill: 2020-2023

Historic Goodwill for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Sep 2023 value amounting to $9.5 million.

  • Insight Molecular Diagnostics' Goodwill fell 49.15% to $9.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.5 million, marking a year-over-year decrease of 49.15%. This contributed to the annual value of $9.5 million for FY2022, which is 49.15% down from last year.
  • As of Q3 2023, Insight Molecular Diagnostics' Goodwill stood at $9.5 million, which was down 0.00% from $9.5 million recorded in Q2 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Goodwill peaked at $24.2 million during Q2 2021, and registered a low of $9.2 million during Q1 2020.
  • Over the past 3 years, Insight Molecular Diagnostics' median Goodwill value was $14.0 million (recorded in 2021), while the average stood at $14.6 million.
  • Its Goodwill has fluctuated over the past 5 years, first surged by 163.82% in 2021, then crashed by 49.15% in 2022.
  • Insight Molecular Diagnostics' Goodwill (Quarterly) stood at $9.2 million in 2020, then soared by 103.37% to $18.7 million in 2021, then tumbled by 49.15% to $9.5 million in 2022, then slumped by 49.15% to $9.5 million in 2023.
  • Its last three reported values are $9.5 million in Q3 2023, $9.5 million for Q2 2023, and $9.5 million during Q1 2023.